COLLABORATION AGREEMENT BY AND BETWEEN AMGEN INC. AND NOVARTIS PHARMA AG DATED APRIL 21, 2017Collaboration Agreement • July 26th, 2017 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Collaboration Agreement (this “Agreement”), effective as of April 21, 2017 (the “Effective Date”), is by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, U.S.A. (“Amgen”), and Novartis Pharma AG, a Swiss company having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Amgen and Novartis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT No. 2 to the Exclusive License and Collaboration Agreement between Novartis Pharma AG and Amgen Inc.Exclusive License and Collaboration Agreement • July 26th, 2017 • Amgen Inc • Biological products, (no disgnostic substances)
This Amendment No. 2 (“Amendment”) is entered into as of April 21, 2017 (“Amendment No. 2 Effective Date”) by and between Novartis Pharma AG a Swiss corporation having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA (“Amgen”). Novartis and Amgen are each referred to individually as a “Party” and together as the “Parties”.
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN AMGEN INC. AND NOVARTIS PHARMA AGExclusive License and Collaboration Agreement • July 26th, 2017 • Amgen Inc • Biological products, (no disgnostic substances) • New York
This Exclusive License and Collaboration Agreement (this “Agreement”), effective as of August 28, 2015 (the “Effective Date”), is by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, U.S.A. (“Amgen”), and Novartis Pharma AG, a Swiss company having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Amgen and Novartis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT No. 1 to the Exclusive License and Collaboration AGREEMENT between Novartis Pharma AG and Amgen Inc.Exclusive License and Collaboration Agreement • July 26th, 2017 • Amgen Inc • Biological products, (no disgnostic substances)
This Amendment No. 1 (“Amendment”) is entered into as of April 21, 2017 (“Amendment Effective Date”) by and between Novartis Pharma AG, a Swiss corporation having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”), and Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive, Thousand Oaks, California 91320-1799, USA (“Amgen”). Novartis and Amgen are each referred to individually as a “Party” and together as the “Parties”.
